Oppenheimer & Co. Inc. acted as Joint Bookrunner on Veru Inc.'s $37,950,000 Confidentially Marketed Follow-On Offering
Veru Inc. (“Veru”) (Nasdaq: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases and cancer, announced the pricing of its underwritten public offering of 45,833,333 shares of its common stock at a price of $0.72 per share on Thursday. Gross proceeds, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $33.0 million. Veru granted the underwriters a 30-day option to purchase up to 6,874,999 additional shares of common stock at the public offering price, less underwriting discounts and commissions; the underwriters have exercised this option in full, resulting in a total offering size of $38.0 million.

Veru recently announced pipeline reprioritization plans and will be advancing its proprietary novel agent, enobosarm, a selective androgen receptor modulator (SARM), into a Phase 2b clinical trial in combination with GLP-1 weight loss drugs to evaluate its safety and efficacy to further increase fat loss while preventing the significant muscle wasting that may occur with GLP-1 weight loss drugs.

Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences
DISCLOSURES
This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
2023 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6167995.1